Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services

Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services 
NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: Medicure Inc. 
OTCQB SYMBOL:  MCUJF
TSX VENTURE SYMBOL:  MPH 
APRIL 14, 2014 
Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services 
WINNIPEG, MANITOBA--(Marketwired - April 14, 2014) - Medicure Inc.
("Medicure" or the "Company") (TSX
VENTURE:MPH)(OTCQB:MCUJF), a specialty pharmaceutical company, today announced
it has entered into an arrangement with Knight Therapeutics Inc. (TSX
VENTURE:GUD), under which Knight will provide advisory services to help advance
Medicure's U.S. specialty pharmaceutical business and corporate
development initiatives.  
"Medicure is pleased to have the opportunity to work with Jonathan Ross
Goodman, co-founder of Paladin Labs Inc. and CEO of Knight Therapeutics
Inc." stated Dr. Albert D. Friesen, CEO and Chair of Medicure Inc.
"We look forward to benefitting from the depth of experience and networks
that he has built up in establishing and growing a successful specialty
pharmaceutical business." 
Jonathan Ross Goodman, CEO of Knight Therapeutics Inc. commented, "I am
pleased to leverage my skills and experience to help Medicure further grow its
business."  
About Knight Therapeutics 
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products for the Canadian and world markets. Knight
Therapeutics' shares began trading on the TSX-V on March 3, 2014 under the
symbol GUD. For more information about Knight Therapeutics, please visit the
company's web site at www.gud-knight.com or at www.sedar.com  
About Medicure Inc.  
Medicure is a specialty pharmaceutical company focused on the development and
commercialization of novel small molecule therapeutics. The primary focus of
the Company and its subsidiaries is the marketing and distribution of AGGRASTAT
(tirofiban HCl) for non-ST elevation acute coronary syndrome in the United
States, where it is sold through the Company's U.S. subsidiary, Medicure
Pharma, Inc. For more information on Medicure please visit www.medicure.com.  
To be added to Medicure's e-mail list, please visit:
http://medicure.com/newsreleases.html  
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. Forward Looking Information
Statements contained in this press release that are not statements of
historical fact, including, without limitation, statements containing the words
"believes", "may", "plans", "will",
"estimates", "continues", "anticipates",
"intends", "expects" and similar expressions, may
constitute "forward-looking information" within the meaning of
applicable Canadian and U.S. federal securities laws (such forward-looking
information and forward-looking statements are hereinafter collectively
referred to as "forward-looking statements"). Forward-looking
statements, including the potential for Medicure to attain material benefit
from the advisory services of Knight Therapeutics, are based on the current
assumptions, estimates, analysis and opinions of management of the Company made
in light of its experience and its perception of trends, current conditions and
expected developments, as well as other factors which the Company believes to
be relevant and reasonable in the circumstances. Inherent in forward-looking
statements are known and unknown risks, uncertainties and other factors beyond
the Company's ability to predict or control that may cause the actual
results, events or developments to be materially different from any future
results, events or developments expressed or implied by such forward-looking
statements, and as such, readers are cautioned not to place undue reliance on
forward-looking statements.  
Such risk factors include, among others, the Company's future product
revenues, stage of development, additional capital requirements, risks
associated with the completion and timing of clinical trials and obtaining
regulatory approval to market the Company's products, the ability to
protect its intellectual property, dependence upon collaborative partners,
changes in government regulation or regulatory approval processes, and rapid
technological change in the industry. Such statements are based on a number of
assumptions which may prove to be incorrect, including, but not limited to,
assumptions about: general business and economic conditions; the impact of
changes in Canadian-US dollar and other foreign exchange rates on the
Company's revenues, costs and results; the timing of the receipt of
regulatory and governmental approvals for the Company's research and
development projects; the availability of financing for the Company's
commercial operations and/or research and development projects, or the
availability of financing on reasonable terms; results of current and future
clinical trials; the uncertainties associated with the acceptance and demand
for new products and market competition. The foregoing list of important
factors and assumptions is not exhaustive. The Company undertakes no obligation
to update publicly or otherwise revise any forward-looking statements or the
foregoing list of factors, other than as may be required by applicable
legislation. Additional discussion regarding the risks and uncertainties
relating to the Company and its business can be found in the Company's
other filings with the applicable Canadian securities regulatory authorities or
the US Securities and Exchange Commission, and in the "Risk Factors"
section of its Form 20F for the year ended May 31, 2013.  
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
Medicure Inc.
Dawson Reimer
President & COO
888-435-2220
204-488-9823
info@medicure.com 
INDUSTRY:  Medical and Healthcare - Medical Devices, Pharmaceuticals and
Biotech - Equipment and Supplies 
SUBJECT:  BFC 
-0-
-0- Apr/14/2014 12:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.